Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis

@article{Eng2012VascularEG,
  title={Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis},
  author={Lawson Eng and Abul Kalam Azad and Steven Habbous and Vincent Pang and Wei Xu and Anke H. Maitland‐van der Zee and Sevtap Savas and Helen J Mackay and Eitan Amir and Geoffrey Liu},
  journal={Clinical Cancer Research},
  year={2012},
  volume={18},
  pages={4526 - 4537}
}
Angiogenesis is an important host process that interacts with cancer cells to promote growth, invasion, and metastasis. Numerous therapeutic agents targeting the VEGF pathway have been developed. Host variability in VEGF pathway can influence angiogenesis-dependent signaling, altering sensitivity to antiangiogenic drugs and prognosis. A systematic review and meta-analysis was conducted (May 1990–July 2011). Eligible studies involved cancer patients and compared polymorphisms in the VEGF pathway… 
View on AACR
clincancerres.aacrjournals.org
47 Citations
Highly Influential Citations
1
Background Citations
10
Methods Citations
2
Results Citations
1

Tables from this paper

47 Citations

Citation Type

Citation Type

Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
TLDR
Evidence is provided that functional germline polymorphisms in the VEGF pathway may help to predict outcome in mCRC patients who undergo oxaliplatin/5-fluorouracil chemotherapy, and the importance of VEGFR2 rs2071559 and KISS1 rs71745629 in modulating these outcomes is supported.
Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.
TLDR
An update is presented on the potential role of VEGF SNPs as prognostic and/or predictive markers in patients with breast cancer and how these SNPs may be of predictive value in patients receiving agents targeting the V EGF pathway.
Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients
TLDR
Findings reinforce the potential clinical value of germline variants in VEGFA and VEGFR2 and show for the first time variants in ITGAV and MAPK11 as promising prognostic markers in metastatic NSCLC patients receiving platinum-based chemotherapy.
The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis.
Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.
TLDR
Analysis of VEGF genetic polymorphisms in frail elderly patients may further help in tailoring an angiogenic pharmacological strategy, and in improving the ability to better understand prognosis during therapy-related to cancer.
Association of Genetic Variants in ANGPT/TEK and VEGF/VEGFR with Progression and Survival in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy or Radiochemotherapy
TLDR
The data suggest that certain germline variants in ANGPT2/TEK and VEGF/VEGFR2 axes may have predictive and prognostic potential in HNSCC treated with radiation or chemoradiation.
Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Polymorphisms in the vascular endothelial growth factor (VEGF)/angiogenesis pathway have been implicated previously in cancer risk, prognosis and response to therapy including in esophageal…
No associations of a set of SNPs in the Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinase (MMP) genes with survival of colorectal cancer patients
TLDR
While the genetic variations in the VEGF and MMP genes are attractive candidates as prognostic markers, this study showed no evidence of associations of a large set of SNPs in these genes and overall survival of colorectal cancer patients in this study.
Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy
TLDR
The findings indicate that the VEGF-A ATTGC haplotype may predict clinical recurrence in prostate cancer patients treated with radiotherapy.
MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.
TLDR
Findings suggest that downregulation of miR-497 may contribute to angiogenesis in ovarian cancer, and may be a promising candidate target for prevention and treatment of ovarian cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 85 REFERENCES
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
TLDR
A review of the role of SNPs in the VEGF gene as predictive and prognostic markers for major solid tumors, including the breast, non-small cell lung, colorectal, and prostate cancers, finds there is lack of unanimity in findings.
Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival
TLDR
VEGF gene polymorphisms were found to be an independent prognostic marker for Greek CRC patients and no correlation was found between these variants and tumor characteristics like size, histological grading, positive regional lymph node metastases or tumor stage.
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
  • B. Schneider, Molin Wang, +13 authors K. Miller
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
The data support an association between VEGF genotype and median OS as well as grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer.
Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer
TLDR
VEGF gene polymorphisms were found to be an independent prognostic marker for patients with colorectal cancer and can help identify patient subgroups at high risk of a poor disease outcome.
Prognostic Importance of Vascular Endothelial Growth Factor-A Expression and Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancer
TLDR
Vascular endothelial growth factor polymorphisms +405G/C and VEGF expression seem to have independent prognostic importance, and heterozygosity of either of the 2 polymorphisms held independent prognosis significance.
Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer
TLDR
First data on VEGF gene polymorphisms in ovarian cancer is presented, showingultaneous carriage of the three investigated homozygous genotypes was shown to be an independent adverse prognosticator of overall survival.
Effect of vascular endothelial growth factor polymorphisms on survival in advanced‐stage non‐small‐cell lung cancer
TLDR
The association between VEGF polymorphisms and overall survival among patients with advanced NSCLC who were treated with at least one cytotoxic regimen at Kyoto University Hospital between 2003 and 2008 was evaluated.
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab
TLDR
The findings of this pilot study suggest that the cyclin D1 A870G and the EGF A61G polymorphisms may be useful molecular markers for predicting clinical outcome in CRC patients treated with single-agent Cetuximab.
VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival.
Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy
TLDR
This study suggests that VEGF -460 C genotypes may be associated with a better survival of LA-NSCLC patients after chemoradiotherapy, and large studies are needed to confirm the findings.
...
1
2
3
4
5
...